Global Specialty Injectable Generics Market Size study, by Type (Drugs, Biologics), by Application (Oncology, Cardiovascular, Infectious Diseases, Central Nervous Systems, Autoimmune Disorders, Others) and Regional Forecasts 2022-2028

Global Specialty Injectable Generics Market Size study, by Type (Drugs, Biologics), by Application (Oncology, Cardiovascular, Infectious Diseases, Central Nervous Systems, Autoimmune Disorders, Others) and Regional Forecasts 2022-2028

Global Specialty Injectable Generics Market is valued at approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Specialty Injectable Generics are drug therapies used for the treatment of chronic conditions that need injection, infusion, or inhalation and are sold as generics.. It includes biologics used in the treatment of a variety of drugs and has the same active ingredients as branded versions, although the inactive contents of the medications can vary. Specialty Injectable Generics are less expensive as compared to traditional drugs and growing number of patents set to expire have led to the adoption of Specialty Injectable Generics across the forecast period. For Instance: as per Statista in 2021, the global specialty generics market was valued at roughly 45 billion dollars in 2018, and it is predicted to grow to nearly 90 billion dollars by 2024. Due to patent expiration, the industry is anticipated to lose 19 billion dollars in prescription medicine sales worldwide by 2022. Following the expiration of a patent, other businesses are permitted to produce less expensive generic versions of the original branded drug. Also, as the key market participants are launching new products and illness prevalence is on the rise are likely to increase the market growth during the forecast period. However, manufacturing biologics and generic injectable is an expensive and difficult operation that may impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Specialty Injectable Generics Market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to the growing number of patents set to expire. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2022-2028. Factors such as key market participants launching new products and rising illness prevalence would create lucrative growth prospects for the Specialty Injectable Generics Market across Asia-Pacific region.

Major Market players included in this report are:
Baxter
Cipla Inc.
Dr. Reddy's Laboratories Ltd
Fresenius Kabi
Hikma Pharmaceuticals PLC
Novartis AG
Par Pharmaceutical
Pfizer Inc
SAGENT Pharmaceuticals
Sun Pharmaceutical Industries Ltd.

The objective of the study is to define Market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the Market. Additionally, the report shall also incorporate available opportunities in micro Markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the Market are explained below:
By Type:
Drugs
Biologics

By Application:
Oncology
Cardiovascular
Infectious Diseases
Central Nervous Systems
Autoimmune Disorders
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Specialty Injectable Generics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Baxter
Cipla Inc.
Dr. Reddy's Laboratories Ltd
Fresenius Kabi
Hikma Pharmaceuticals PLC
Novartis AG
Par Pharmaceutical
Pfizer Inc
SAGENT Pharmaceuticals
Sun Pharmaceutical Industries Ltd.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.